Immunome, Inc. (IMNM)
After hours:
| Previous Close | 14.97 |
| Open | 15.26 |
| Bid | 15.71 x 200 |
| Ask | 15.77 x 100 |
| Day's Range | 15.10 - 16.05 |
| 52 Week Range | 4.50 - 30.96 |
| Volume | |
| Avg. Volume | 842,711 |
| Market Cap | 944.109M |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Immunome Appoints Kinney Horn as Chief Business Officer
BOTHELL, Wash., May 02, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and business development, alliance management, and commercial strategy.
- Business Wire
Immunome Appoints Sandra M. Swain to Board of Directors
BOTHELL, Wash., April 25, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and has served on both public company and non-profit boards.
- Business Wire
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash., April 05, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP). Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research (AACR) Annual Meetin
